uploads/2017/08/Analysts-reco-1.png

What Analysts Recommend for United Therapeutics in August 2017

By

Updated

Recent agreement

In April 2017, United Therapeutics (UTHR) and 3D Systems (DDD) declared their plans to develop solid organ scaffolds for human transplants. United Therapeutics will share its regenerative medicine and organ manufacturing capabilities while 3D Systems will share its 3D printing and precision healthcare expertise to develop solid organ scaffolds for human transplants. As per the agreement between United Therapeutics and 3D Systems, research and development will begin with lung scaffolds.

Article continues below advertisement

Analysts’ recommendations

Thirteen analysts were tracking United Therapeutics in August 2017. Two analysts recommended a “strong buy” while none of the analysts recommended a “buy.” Six analysts recommended a “hold.” Four analysts suggested a “sell,” while one analyst recommended a “strong sell.”

Around ~15% of the analysts tracking United Therapeutics in August 2017 suggested some form of a “buy” rating. On August 28, 2017, United Therapeutics had a consensus 12-month target price of $124.00. Notably, the iShares Core S&P Mid-Cap ETF (IJH) invests ~0.37% of its total portfolio holdings in United Therapeutics.

Peer ratings

A total of 20 analysts were tracking Incyte (INCY) in August 2017. Six of them suggested a “strong buy” and ten analysts recommended a “buy.” Four analysts suggested a “hold,” while none of the analysts recommended a “sell” or “strong sell.”

Around 80% of the analysts covering Incyte in August 2017, recommended some form of a “buy” rating. On August 28, 2017, Incyte had a consensus 12-month target price of $148.07, which represents a ~19.9% return on investment.

Fourteen analysts were tracking Seattle Genetics (SGEN) in August 2017. Two analysts recommended a “strong buy” and three analysts recommended a “buy.” Eight analysts suggested a “hold, ” and one analyst suggested a “sell.”

Around 36% of the analysts tracking Seatle Genetics in August 2017 suggested some form of a “buy” rating. On August 28, 2017, Seatle Genetics had a mean 12-month target price of $58.70, which represents a ~20.4% return on investment.

Advertisement

More From Market Realist